NEW YORK (GenomeWeb) – Immunovia, a Swedish molecular diagnostics company, has initiated a new study with academic collaborators to diagnose early-stage pancreatic cancer in new onset diabetes patients.
Over the next three years, Immunovia and its partners will use the firm's Immray PanCan-d assay to screen 6,000 diabetes patients for pancreatic cancer. The study, called PanDIA-1, is in line with a Swedish government objective to introduce a national screening program for addressing diabetes comorbidities.